Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active ...

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

After Recognify Life Sciences Inc.’s phase IIb failure in treating the cognitive impairment in those with schizophrenia, the indication is no closer to a U.S. FDA approved therapy. The ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

While often seen as a gift, high intelligence can come with its own unique set of challenges, particularly when navigating a ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized ...

As limited aid reaches Gaza, experts warn that malnutrition and starvation is causing long-term, irreversible harm to ...

INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a ...